Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

Clinical trial NCT03823131 · TERMINATED

Trial details

NCT number: NCT03823131
Sponsor: Chase Heaton, MD
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma Unresectable Head and Neck Squamous Cell Carcinoma

Start date: 2019-05-02
Primary completion: 2022-07-31
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.